Spatial and transcriptomic analyses reveal the adverse prognostic impact of regulatory T cells in follicular lymphoma treated with rituximab–lenalidomide
British Journal of Haematology · 16.11.2026
DOI: 10.1111/bjh.70934 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 16.11.2026. Verfasst von Camille Laurent und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire d'Excellence TOUCAN, Centre de Recherches en Cancérologie de Toulouse INSERM U1037, Institut Universitaire Cancer-Oncopole, CHU Toulouse,…. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Labex, Institut Carnot CALYM, The Institute for Follicular Lymphoma Innovation.
Abstract (Originalsprache)
The prognostic impact of the tumour microenvironment in follicular lymphoma (FL) remains controversial. To adress this, we analysed FL samples from patients enrolled in the rituximab lenalidomide versus any chemotherapy (RELEVANCE) trial using RNA‐sequencing (RNA‐seq) and multiplex immunofluorescence (mIF). RNA‐seq analysis ( n = 354) showed that regulatory T‐cell (Treg) signatures were associated with shorter PFS in the whole cohort (HR = 1.56, 95% CI: 1.01–2.41, p = 0.044), particularly in patients treated with rituximab–lenalidomide (LEN) (R2, HR= 1.84, 95% CI: 1–3.37, p = 0.046) but not with rituximab‐chemotherapy (R‐chemo, HR = 1.33, 95% CI: 0.71–2.48, p = 0.365). mIF analysis on tissue microarrays (TMA) ( n = 394) showed that high infiltration of CD3 + /CD4 + /FOXP3 + Tregs was associated with shorter PFS in the overall cohort (HR = 1.951, CI: 1.259–3.024, p = 0.0023 log‐rank test), particularly in the R2 arm (HR = 2.3, CI: 1.2–4.5, p = 0.0097 log‐rank test) and remained significant after FL‐International Prognostic Index (FLIPI) adjustment (HR = 1.843; 95% CI: 1.1–2.8, p = 0.006). Whole‐slide mIF (WSI) performed in 64 selected cases confirmed the adverse prognostic impact of Tregs in R2‐treated patients and further showed that extra‐follicular Treg localization was specifically associated with shorter PFS (HR = 2.87, 95% CI: 1.13–7.28, p = 0.020). These data suggest that high Treg infiltration by mIF is associated with inferior outcome in lenalidomide‐treated FL patients and may have potential value for risk stratification.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratoire d'Excellence TOUCAN, Centre de Recherches en Cancérologie de Toulouse INSERM U1037, Institut Universitaire Cancer-Oncopole, CHU Toulouse, Toulouse, France.
- Institut Paoli-Calmettes, CRCM and Aix-Marseille University, Marseille, France.
- LYSARC, Pierre Bénite, France.
- Hopital Claude Huriez, Lille, France.
ORCID-Profile: Camille Laurent, Marie Tosolini, Nathalie Van-Acker, Pierre Brousset, Franck Morschhauser, Luc Xerri
Förderung
- Labex
- Institut Carnot CALYM
- The Institute for Follicular Lymphoma Innovation
- Lymphoma Academic Research Organisation (LYSARC)
- Bristol Myers Squibb
Zitieren
APA
Laurent, C., Tosolini, M., Guille, A., Tesson, B., Van-Acker, N., Frenois, F. X., Belin-Artola, A., Lesne, B., Brousset, P., BIDIFLY Consortium, Morschhauser, F., & Xerri, L. (2026). Spatial and transcriptomic analyses reveal the adverse prognostic impact of regulatory T cells in follicular lymphoma treated with rituximab–lenalidomide. British Journal of Haematology. https://doi.org/10.1111/bjh.70934
Vancouver
Laurent C, Tosolini M, Guille A, Tesson B, Van-Acker N, Frenois FX, et al. Spatial and transcriptomic analyses reveal the adverse prognostic impact of regulatory T cells in follicular lymphoma treated with rituximab–lenalidomide. British Journal of Haematology. 2026. doi:10.1111/bjh.70934
BibTeX
@article{Laurent2026,
author = {Laurent, Camille and Tosolini, Marie and Guille, Arnaud and Tesson, Bruno and Van-Acker, Nathalie and Frenois, François-Xavier and Belin-Artola, Andrea and Lesne, Bastien and Brousset, Pierre and BIDIFLY Consortium, BIDIFLY Consortium and Morschhauser, Franck and Xerri, Luc},
title = {Spatial and transcriptomic analyses reveal the adverse prognostic impact of regulatory T cells in follicular lymphoma treated with rituximab–lenalidomide},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70934}
}
EUVIMED